Sarepta shares fall 7% after gene therapy maker pauses Elevidys shipments in US
The decision to halt shipments of Elevidys in the U.S. led to a notable decline in Sarepta Therapeutics’ stock value, reflecting investor concerns abo...
Read Full Article →